Loading...

KALV KALVISTA PHARMACEUTICALS INC Earnings Reports 8-K Filing

KLVS

KLV

KALVISTA PHARMACEUTICALS INC

(KALV)

2026 8-K

Financial Results Report

Preliminary Revenue Report

Financial Results

New COO Appointment

Board Appointments

Convertible Notes Offering

Financial Results Revealed

Annual Meeting Update

Financial Statements

New Product Launches

License Agreement

Fiscal Year Change

Financial Results

Management Change

Financial Results

Board Appointment

Revenue Rights Sale

Annual Meeting Results

Management Changes

Financial Results

Lease Agreement

Financial Results

Financial Results

Public Offering

Termination of Sales Agreement

Clinical Data Announcement

Financial Results

Amendment to Certificate of...

Financial Results

Amended Employment Agreement

Financial Results

Appointment of President

External Links:

KalVista Pharmaceuticals, Inc. reported preliminary global net revenues of approximately $35 million for the quarter and $49 million for the eight-month transition period ending December 31, 2025, as announced on January 8, 2026. The final audited financial results may vary from these estimates.

AI Assistant

KALVISTA PHARMACEUTICALS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.